These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21904883)

  • 1. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
    Helzlsouer KJ; Gallicchio L; MacDonald R; Wood B; Rushovich E
    Breast Cancer Res Treat; 2012 Jan; 131(1):277-85. PubMed ID: 21904883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
    Gallicchio L; MacDonald R; Wood B; Rushovich E; Fedarko NS; Helzlsouer KJ
    J Bone Miner Res; 2012 Sep; 27(9):1959-66. PubMed ID: 22508239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
    Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
    Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
    Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
    Martínez N; Herrera M; Frías L; Provencio M; Pérez-Carrión R; Díaz V; Morse M; Crespo MC
    Clin Transl Oncol; 2019 Apr; 21(4):489-498. PubMed ID: 30293230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
    Gallicchio L; MacDonald R; Helzlsouer KJ
    J Cancer Res Clin Oncol; 2013 May; 139(5):837-43. PubMed ID: 23408333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
    Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
    Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
    Bhave MA; Speth KA; Kidwell KM; Lyden A; Alsamarraie C; Murphy SL; Henry NL
    Clin Breast Cancer; 2018 Apr; 18(2):168-174.e2. PubMed ID: 29361424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
    Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors.
    Olufade T; Gallicchio L; MacDonald R; Helzlsouer KJ
    Support Care Cancer; 2015 Feb; 23(2):447-55. PubMed ID: 25128067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
    Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
    Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
    Li H; Sereika SM; Marsland AL; Conley YP; Bender CM
    J Clin Nurs; 2019 Dec; 28(23-24):4560-4571. PubMed ID: 31469461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
    Napoli N; Vattikuti S; Ma C; Rastelli A; Rayani A; Donepudi R; Asadfard M; Yarramaneni J; Ellis M; Armamento-Villareal R
    Breast J; 2010; 16(6):609-16. PubMed ID: 21070438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
    Lustberg MB; Orchard TS; Reinbolt R; Andridge R; Pan X; Belury M; Cole R; Logan A; Layman R; Ramaswamy B; Wesolowski R; Berger M; Patterson E; Loprinzi C; Shapiro CL; Yee L
    Breast Cancer Res Treat; 2018 Feb; 167(3):709-718. PubMed ID: 29101597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Servitja S; Nogués X; Prieto-Alhambra D; Martínez-García M; Garrigós L; Peña MJ; de Ramon M; Díez-Pérez A; Albanell J; Tusquets I
    Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
    Castel LD; Hartmann KE; Mayer IA; Saville BR; Alvarez J; Boomershine CS; Abramson VG; Chakravarthy AB; Friedman DL; Cella DF
    Cancer; 2013 Jul; 119(13):2375-82. PubMed ID: 23575918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.